Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review

Supportive Care in Cancer

Volumn 22, Issue 8, 2014, Pages 2261-2269

  Mols, Floortje ^a,b   Beijers, Tonneke ^c   Vreugdenhil, Gerard ^c,d   Van De Poll Franse, Lonneke ^a,b  

^a TILBURG UNIVERSITY   (Netherlands)

^b The Netherlands   (Netherlands)

^c MÁXIMA MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Chemotherapy induced peripheral neuropathy; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVOR; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG INDUCED DISEASE; ENDOMETRIUM CANCER; HUMAN; LUNG CANCER; LYMPHOMA; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; HUMANS; INDUCTION CHEMOTHERAPY; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; QUALITY OF LIFE;

EID: 84905103887     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2255-7     Document Type: Review

References (39)

1. Gutiérrez-Gutiérrez G et al (2010) Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol 12(2):81-91
2. Kannarkat G, Lasher E, Schiff D (2007) Neurologic complications of chemotherapy agents. Curr Opin Neurol 20(6):719-725 (Pubitemid 350085017)
3. Sukel MP et al (2008) Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands. Eur J Cancer 44(13):1846-1854
4. Dassen AE et al (2010) Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer 46(6):1101-1110
5. Elferink MA et al (2010) Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989-2006. Eur J Cancer 46(8):1421-1429
6. van Steenbergen LN et al (2012) Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in The Netherlands. Ann Oncol 23(11):2805-2811
7. Beijers AJ, Jongen JL, Vreugdenhil G (2012) Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med 70(1):18-25
8. Beijers AJM, Mols F, Vreugdenhil G (2014) A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer. doi:10.1007/s00520-014-2242-z
9. Markman M (1996) Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of life. J Cancer Res Clin Oncol 122(9):511-512
10. Tofthagen C (2010) Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med 13(11):1389-1391
11. Bakitas MA (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56(5):323-331
12. Bezjak A et al (2004) Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol 22(22):4595-4603 (Pubitemid 41185127)
13. Brundage M et al (2012) Health-related quality of life in recurrent platinum-sensitive ovarian cancer - results from the CALYPSO trial. Ann Oncol Off J Eur Soc Med Oncol / ESMO 23(8):2020-2027
14. Bruner DW et al (2007) Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. Qual Life Res Int J Qual Life Asp Treat Care and Rehab 16(1):89-100 (Pubitemid 46046740)
15. Butler L et al (2004) Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol Off J Am Soc Clin Oncol 22(12):2461-2468 (Pubitemid 41115405)
16. Calhoun EA et al (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13(6):741-748 (Pubitemid 38235217)
17. Cavaletti G et al (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24(2):454-462
18. Cella D et al (2003) Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). Cancer 98(4):822-831 (Pubitemid 36959280)
19. Cella D et al (2010) Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 119(3):531-537
20. Driessen CM et al (2012) Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 20(4):877-881
21. Griffith KA et al (2014) Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations. Support Care Cancer 22(5):1161-1169
22. Hershman DL et al (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767-774
23. Hilpert F et al (2005) Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy - a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 13(10):797-805 (Pubitemid 41414020)
24. Kautio AL et al (2008) Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manag 35(1):31-39
25. Kim BJ et al (2010) Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Qual Life Res 19(8):1097-1103
26. Lee SM et al (2009) Randomized double-blind placebo-controlled trial of thalidomide in combinationwith gemcitabine and Carboplatin in advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(31):5248-5254
27. Mols F et al (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. doi:10.1200/JCO.2013. 49.1514
28. Morita S et al (2003) Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model. Jpn J Clin Oncol 33(9):470-476 (Pubitemid 43102834)
29. Ostchega Y, Donohue M, Fox N (1988) High-dose cisplatin-related peripheral neuropathy. Cancer Nurs 11(1):23-32
30. Ramchandren S et al (2009) Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst: JPNS 14(3):184-189
31. Richter R et al (2012) Health-related quality of life during sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: a multicenter phase II study of the North Eastern German Society of Gynecological Oncology. Anticancer Res 32(9):3969-3976
32. Shimozuma K et al (2012) Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer Off JMultinatl Assoc Support Care Cancer 20(12):3355-3364
33. Smith EM et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA J Am Med Assoc 309(13):1359-1367
34. Sorbe B et al (2012) A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation. Int J Oncol 40(3):773-781
35. Tofthagen C (2010) Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 14(3):E22-E28
36. Wenzel LB et al (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol Off J Am Soc Clin Oncol 25(4):437-443 (Pubitemid 350002993)
37. Mols F et al (2005) Quality of life among long-term breast cancer survivors: a systematic review. Eur J Cancer 41(17):2613-2619 (Pubitemid 41613712)
38. Den Oudsten BL, VanHeck GL, De Vries J (2007) Quality of life and related concepts in Parkinson's disease: a systematic review. Mov Disord 22(11):1528-1537 (Pubitemid 47477911)
39. Pachman DR et al (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90(3):377-387